Quote:Leronlimab (LRM) is a humanized monoclonal antibody that blocks CCR5 and reduces TNBC metastasis by >98% in preclinical models.
Most lethality in cancer comes from mets. If the CRC study can show even remotely similar efficacy in people, and in a second cancer, one could make a case for Leron becoming an adjuvant for all first-line treatment vs. all aggressive solid-tumor cancers.
Wall it in, shrink it, and help create a way for the immune system to destroy it.